Showing 5551-5560 of 7758 results for "".
- Autoimmune Skin Diseases Linked to Better Cancer Survival: Studyhttps://practicaldermatology.com/news/autoimmune-skin-diseases-linked-to-better-cancer-survival-study/2475516/Patients with autoimmune skin diseases (ASDs) who undergo cancer treatment may experience improved survival outcomes compared to those without ASDs, a new population-based study from Taiwan suggests. Using data derived from Ta
- Study: Sofpironium Gel Effective for Axillary Hyperhidrosishttps://practicaldermatology.com/news/phase-3-data-support-sofpironium-gel-for-axillary-hyperhidrosis/2475489/Sofpironium topical gel, 12.45%, showed efficacy and tolerability in treating primary axillary hyperhidrosis, according to pooled results from two pivotal Phase 3 trials. Researchers for the combined analysis of the Cardigan
- Shifting the Perspective: Addressing Social Determinants and Pigmentary Impact in Atopic Dermatitishttps://practicaldermatology.com/news/shifting-the-perspective-addressing-social-determinants-and-pigmentary-impact-in-atopic-dermatitis/2475416/In her presentation “Viewing Atopic Dermatitis Through a Different Lens,” Candrice Heath, MD, FAAD, an associate professor of dermatology at Howard University, used atopic dermatitis (AD) as a case study to examine how social determinants of health (SDOH), skin tone diversity, and structural ineq
- Review: Air Quality and Weather Linked to Dermatitis Severityhttps://practicaldermatology.com/news/review-air-quality-and-weather-linked-to-dermatitis-severity/2475392/Increased exposure to air pollutants and extreme temperatures is associated with greater population burden of atopic dermatitis (AD), according to a systematic review published in JAMA Dermatology.
- Dupilumab Linked to Higher Psoriasis Risk in AD Patientshttps://practicaldermatology.com/news/dupilumab-linked-to-higher-psoriasis-risk-in-ad-patients/2475230/Patients with atopic dermatitis (AD) prescribed dupilumab face a higher risk of developing psoriasis compared to those receiving other systemic agents, according to a large retrospective cohort study in JAMA Dermatology.
- NEMLUVIO Demonstrates Durable Efficacy and Safety in Atopic Dermatitishttps://practicaldermatology.com/news/nemluvio-demonstrates-durable-efficacy-and-safety-in-atopic-dermatitis/2475110/New two-year interim data from the ARCADIA long-term extension study of NEMLUVIO (nemolizumab) showed sustained improvements in skin and itch outcomes. The therapy was approved by the FDA in December 2024 for the treatment of
- Study: Strontium Cream Could Help Manage Pruritus in HShttps://practicaldermatology.com/news/Study-Strontium-Cream-Could-Help-Manage-Pruritus-HS/2475142/Strontium cream demonstrated promise as a therapeutic option for managing pruritus in hidradenitis suppurativa (HS), according to new research published in the Journal of Clinical and Aesthetic Dermatology. Statistical analysis of baseline and 1-week post-intervention surveys amon
- Bimekizumab 3-Year Data Shows Lasting Efficacy, Control of Inflammation for PsA, axSpAhttps://practicaldermatology.com/news/Bimekizumab-3-Year-Data-Shows-Lasting-Efficacy-Control-Inflammation-PsA-axSpA/2475126/Bimekizumab (BIMZELX®) demonstrated sustained control of inflammation and deep efficacy in patients living with psoriatic arthritis (PsA) and active axial spondyloarthritis (axSpA), according to new 3-year data from phase 3 trials and open-label extensions in adults with active PsA and active axS
- Researcher Elaborates on Vitamin D Pretreatment to Enhance PDT for AKhttps://practicaldermatology.com/news/Researcher-Elaborates-Vitamin-D-Pretreatment-Enhance-PDT-AK/2475053/Vitamin D pretreatment can enhance photodynamic therapy (PDT) treatment of actinic keratoses (AK), and vitamin D receptor alleles correlate with serum vitamin D levels and squamous neoplasia, dermatology resident Taylor Bullock, MD, showed in a presentation at the Noah Worcester Dermatological So
- INT for Melanoma 'Coming Very Fast,' Dr. Joel Claveau Says at Noah Worcester Meetinghttps://practicaldermatology.com/news/INT-Melanoma-Coming-Very-Fast-Dr-Joel-Claveau-Says-Noah-Worcester-Meeting/2475044/The next big thing in melanoma treatment may be individualized neoantigen therapy (INT)—according to Joel Claveau, MD, in a presentation at the Noah Worcester Dermatological Society meeting in Quebec City, Quebec. “It’s almost rocket science, but it’s really coming very fast,” Dr. Claveau